Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 127,725

Document Document Title
WO/2017/178340A1
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, ...  
WO/2017/177838A1
The present invention relates to substituted 2,4-(1H, 3H)-pyrimidinedione derivatives and the use thereof as therapeutically effective poly(ADP-ribose)polymerase (PARP) inhibitors. In particular, the present invention relates to the use ...  
WO/2017/178341A1
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, p...  
WO/2017/179602A1
The present invention addresses the problem of providing a brain function-improving composition for newborns, particularly newborns who are just after birth. According to the present invention, a brain function-improving agent for newbor...  
WO/2017/177896A1
Disclosed in the present invention are a compound represented by formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition o...  
WO/2017/179647A1
A peptide is provided which has a binding inhibitory function that inhibits binding between amylospheroids (ASPD) and neurons. The polypeptide, represented by expression (I) or (II), is synthesized, isolated or purified. X1X2X3X4 (I) In ...  
WO/2017/179707A1
The present invention provides a novel combination for improving frailty or a novel combination for suppressing reduction in skeletal muscle mass. More specifically, the present invention provides a combination for improving frailty or a...  
WO/2017/179644A1
Disclosed are: a cognitive function-remedying agent which contains, as active ingredients, vitamin A, vitamin B compounds (B1, B2, B6 and B12), vitamin C, vitamin D, vitamin E, zinc, magnesium, pantothenic acid, biotin and folic acid; an...  
WO/2017/178338A1
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, ...  
WO/2017/178810A1
The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA ...  
WO/2017/178515A1
The present invention relates to piperidinylalkylamide derivatives having dual pharmacological activity towards both the sigma (σ) receptor and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical com...  
WO/2017/178343A1
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, pa...  
WO/2017/178456A1
The invention relates to a carotenoid for use in the treatment or prevention of stress induced conditions, and in particular it relates to the treatment or prevention of a disease mediated by glucocorticoid receptor activity. The inventi...  
WO/2017/178685A1
The invention relates to the use of a composition comprising an aminosalicylate in the production of a drug for the relief, improvement, prevention and/or treatment of diseases or disorders related to an aggregating protein, specifically...  
WO/2017/177148A1
Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibo...  
WO/2017/176619A1
This document provides materials and methods for treating a damaged optic nerve in a mammal to restore visual function comprising administering a population of induced pluripotent stem cell-derived oligodendrocyte precursor cells. This d...  
WO/2017/176109A1
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic a...  
WO/2017/173800A1
The present invention provides an application using an MAPK signal pathway inhibitor for preparing a pharmaceutical product for delaying dopaminergic neuron degeneration, and specifically provides an application in preparing a pharmaceut...  
WO/2017/174999A1
There are described novel compounds of formula I: in which R1, R2, R3, R4, R5, X1 and X2 are each as herein defined, for use in the treatment or alleviation of an RAR mediated condition: and methods related thereto.  
WO/2017/177240A1
The present invention provides a plant-based medicament for treatment for opiate addiction having reduction ability on addiction liability of opiate narcotics. The medicament according to the invention is safe, non-addictive, has reducti...  
WO/2017/173604A1
Provided herein are compounds of the formula (I) : as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containin...  
WO/2017/173973A1
The present disclosure provides a nitrogen heterocyclic tryptamine ketone derivative and application thereof as an indoleamine 2,3-dioxygenase 1 (IDO1) and/or tryptophan 2,3-dioxygenase (TDO) inhibitor. The derivative is represented by f...  
WO/2017/175457A1
Provided is a therapeutic/prophylactic agent for Alzheimer disease, which uses a safe food-derived compound and which has an excellent therapeutic/preventive effect. This therapeutic/prophylactic agent for Alzheimer disease is formed by ...  
WO/2017/177160A1
Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid p...  
WO/2017/174847A1
The invention relates to a nanoparticle comprising: (i) between 60 wt.-% and 99 wt.-% sorbitan ester, relative to the total weight of the nanoparticle; (ii) a positively charged substance; and (iii) an miRNA. The invention also relates t...  
WO/2017/176108A1
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic a...  
WO/2017/176385A1
Provided herein are compositions, devices, kits and methods for the diagnosis and treatment of brain injury. Certain agents herein detect, inhibit, suppress, abrogate or modulate acute or chronic immune response associated with brain inj...  
WO/2017/176962A1
The invention provides substituted pyrrolo[1,2-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorder...  
WO/2017/176961A1
The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorder...  
WO/2017/174787A1
The invention relates to a tobacco leaf extract containing, relative to the total weight of the extract, at least 5 wt.-% proteins essentially free of molecules with a molecular mass of less than 10 kDa. The invention also relates to a p...  
WO/2017/173534A1
33 ABSTRACT The present disclosure provides delivery systems for delivering FK506 locally to damaged nerve sites. Particulate FK506 incorporated into a fibrin gel, with the amount of FK506 sufficient to give an FK506 release rate over at...  
WO/2017/176960A1
The invention provides substituted pyrazolo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorde...  
WO/2017/167168A1
Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids having more than three galloyl moieties, methods of preparing such, and uses the...  
WO/2017/167895A1
The present invention relates to a composition comprising choline for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connectivity; (iv) intellectual pot...  
WO/2017/172811A1
The disclosure provides new, stable, pharmaceutically acceptable co-crystal forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-h exahydro-1H,7H-pyrido[3´ 4´:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together w...  
WO/2017/167417A1
The present invention relates to a composition comprising choline for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connectivity; (iv) intellectual pot...  
WO/2017/167898A3
The present invention relates to a composition comprising at least one vitamin, for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii)brain structure; (iii)brain connectivity; (iv)intel...  
WO/2017/173049A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.  
WO/2017/172771A2
A method of treating an IL-12/23 -related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4...  
WO/2017/170926A1
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...  
WO/2017/167415A1
The present invention relates to a composition comprising one or more fatty acid derivatives for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connecti...  
WO/2017/173442A1
Topical compositions are provided containing one or more agents to treat and/or prevent pain. The compositions of the invention can be topically administered to a subject to treat pain, for example, neuropathic pain.  
WO/2017/168137A1
There is provided herein a compound of formula I (I) or a tautomer and/or pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a neurodegenerative disorder, wherein X, Y, Z, R1, R2 and n have meanings as pr...  
WO/2017/172771A3
A method of treating an IL-12/23 -related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4...  
WO/2017/169966A1
[Problem] The purpose of the present invention is to provide a strain of Bifidobacteria having a high serotonin-secretion-promoting ability, and a food and/or beverage containing a treated form of the Bifidobacterium. [Solution] The inve...  
WO/2017/173048A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin- related disorders.  
WO/2017/168244A1
The present application relates to a method of treating Parkinson's disease by administering a mouth-dissolving composition of N-propargylamine derivative, such as rasagiline or a pharmaceutically-acceptable salt thereof.  
WO/2017/167416A1
The present invention relates to a composition comprising a phospholipid or a metabolic precursor or metabolite thereof, or a mixture thereof, for use in promoting, supporting or optimizing one or more of the following: (i) de novo myeli...  
WO/2017/172914A1
The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In p...  
WO/2017/168390A3
Method for preventing or treating neurodegenerative diseases, based in treating in vitro or ex vivo CD4+ T cells obtained from a subject, with a dopamine D3 (D3R) receptor inhibitor compound, and reincorporating the pre-treated CD4+ T ce...  

Matches 401 - 450 out of 127,725